ClinicalTrials.gg
RecruitingNCT05776641Updated Jun 18, 2026

Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease

An interventional study of GENUS in Alzheimer Disease and Family Members, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.

Planned enrollment
2nd of 25
200 · median 20
Started
2024
with 3 others
No phase
16 of 29
5 open now
Registered
19th of 29
by date

Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2024, is one of 16 with no phase, and was the 19th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alzheimer Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease.

Read the detailed description

The investigators are recruiting participants aged 55+ with normal memory who have or had a close family member with Alzheimer's disease. 200 participants will undergo a blood test and a subset will undergo an amyloid PET scan and only 50 participants who have cerebral amyloid deposits will continue in the study. Neither the participant nor the investigators will know whether the participant is receiving sham or active stimulation. Participants will use the device for 12 months at home, for 60 minutes each day when they are awake. Participants will come to the Massachusetts General Hospital in Boston for 4-6 visits: before starting the stimulation, at 6 months, and after 12 months of usage. The participants will undergo PET scans, MRI, EEG, blood tests and memory tests and questionnaires at each visit to monitor progress. In addition, people may elect to allow for us to study their cerebral spinal fluid. Participants will also wear a "fitbit" like watch to monitor sleep and activity throughout the study. The goal of this study is to evaluate whether stimulation with our device at 40Hz will reduce AD pathology in the brain.

03

Conditions studied

  • Alzheimer Disease
  • Family Members

Browse trials for

Keywords

  • Cognitively normal
  • Alzheimer's disease
  • Gamma
  • Amyloid
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 55 - 90 years of age, inclusive.
  2. Immediate family history of Alzheimer's disease.
  3. (MMSE) score of 27 or greater at baseline or expected score range for cognitively normal adjusted for education level.
  4. Clinical Dementia Rating Global Score of 0 at baseline.
  5. Delayed Recall score on the Logical Memory IIa subtest of 8 to 15 at baseline or expected score range for cognitively normal adjusted for education level.
  6. Low serum amyloid levels at baseline.
  7. Elevated fibrillar amyloid using 11C PiB PET at baseline between 20 - 70 CL.
  8. Willing and able to undergo MRI brain and PET brain scans.
  9. Adequate visual and auditory acuity to allow for neuropsychological testing.
  10. Able to comply with neuropsychological testing and other study procedures in opinion of site PI.
  11. Willing and able to complete baseline assessments, and willing to participate in 13-month study protocol.
  12. Willing to provide blood samples at specified timepoints. Willing to consider contributing CSF samples at specified timepoints, if asked.

Exclusion criteria

Exclusion Criteria:

  1. MRI , such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
  2. High myopia \< -7 diopters, or untreated cataracts that affect vision.
  3. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
  4. For subjects agreeing to undergo lumbar punctures, history of bleeding disorders or laboratory results indicating low levels are exclusionary for the procedure.
  5. Concomitant medications:

    1. Treatment with NMDA antagonists.
    2. For subjects undergoing lumbar puncture, current use of warfarin or similar anti-coagulants is exclusionary for the procedure.
  6. Clinical conditions:

    1. History of seizure or medical diagnosis of epilepsy.
    2. Female subjects who are pregnant or currently breastfeeding.
    3. History of severe allergic or anaphylactic reactions.
    4. Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.
    5. Neurodegenerative disorder associated with cognitive impairment.
    6. Renal disease.
  7. MR imaging findings such as stroke, tumor, leukoencephalopathy that could preclude meaningful analyses of clinical and imaging data in the opinion of the site PI, such as:

    1. Severe leukoencephalopathy seen on MRI.
    2. Relevant structural abnormality (i.e., normal pressure or obstructive hydrocephalus, hypoxic ischemic lesions, hemorrhages, tumors, malformations).
    3. Cerebral amyloid angiopathy, evidenced by T2* or other susceptibility weighted-MRI.
  8. Laboratory findings, if known (study does not perform testing) suggestive of systemic illness such as renal disease.
  9. Site investigator's discretion, if s/he feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Active GENUS light and sound

    The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.

    Device: GENUS

  • Sham comparator
    Sham GENUS light and sound

    The device is the same as the active device but it delivers light and sound at different frequencies.

    Device: GENUS

Interventions

  • DeviceGENUS

    Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months

06

What researchers measure

Primary outcomes

  1. Changes in brain amyloid deposition over the study period, as measured by PiB PET.

    The investigators will evaluate changes from baseline in amyloid deposition by using Pittsburgh compound B (PiB) PET, which is a standard for AD trial biomarkers, to assess progression towards AD with active or sham treatment.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Changes in brain tau deposition

    The investigators will evaluate changes from baseline in tau deposition by using MK-6240 PET

    Time frame: Baseline to 12 months

  2. Changes in brain structure using structural MRI

    The investigators will evaluate changes in brain structure using structural MRI. Preliminary data show prevention of brain atrophy after 3 months of GENUS as measured by ventricular dilation and hippocampal volume. Using structural MRI, the investigators will evaluate brain volume, cortical thickness and ventricular volume.

    Time frame: Baseline to 12 months

  3. Changes in brain electrical activity

    The investigators will evaluate brain electrical activity using longitudinal EEG (ie, gamma band power)

    Time frame: Baseline to 12 months

  4. Changes in brain connectivity by functional MRI

    The investigators will evaluate connectivity using resting state functional MRI to assess changes in brain networks (ie, default mode network).

    Time frame: Baseline to 12 months

  5. Changes to rest-activity parameters using actigraphy.

    Actigraphy will be used to evaluate rest-activity parameters (ie, interdaily stability

    Time frame: Baseline to 12 months

  6. Changes in blood biomarkers of AD

    Changes in Alzheimer's blood-based biomarkers (e.g. plasma Aβ42/Aβ40 ratio, Aβ42, Aβ40, p-tau, and neurofilament light) assessed by longitudinal blood sample collection

    Time frame: Baseline to 12 months

  7. Compliance of usage as measured by timestamp tracking and eye-tracking technology

    The device contains both a time-counter to track 'on time' and a camera that records images for eye-tracking, to quantitatively determine compliance with looking directly at the device. This method also quantifies whether the subjects are awake for the duration of treatment. Previous work with healthy older adults and a small cohort of mild AD patients have had 90% compliance.

    Time frame: Baseline to 12 months

  8. Change from baseline in CSF levels of amyloid and tau.

    Lumbar puncture and CSF collection will be optional for participants, but will be informative as to the investigator's hypothesized mechanisms of clearance.

    Time frame: Baseline to 12 months

Other outcomes

  1. Changes in CSF flow, as measured by BOLD fMRI

    The investigators will evaluate changes from baseline in CSF flow by using BOLD fMRI. CSF flow has been linked to amyloid clearance from the brain, and brain waste clearance mechanisms such as blood vessel dilation and increased glymphatic drainage are activated after 40-Hz light and sound stimulation in our preliminary mouse studies

    Time frame: Baseline to 12 months

  2. Change from baseline in integrity of white matter tracks and myelination as measured by diffusion MR imaging.

    It is hypothesized that neuromodulation causes changes in synaptic plasticity. The investigators will evaluate plasticity and structural measures of connectivity using diffusion imaging techniques.

    Time frame: Baseline to 12 months

  3. Changes in performance on memory tasks, particularly those that are reliant on visual or auditory pathways, using a neuropsychological test battery.

    The investigators will evaluate changes from baseline in performance on memory tasks using a comprehensive neuropsychological battery designed to evaluate pre-clinical AD populations. Preliminary data showed that 3 months of treatment in mild AD patients led to improved performance on an associative memory task.

    Time frame: Baseline to 12 months

  4. Change from baseline in gamma oscillations as measured by EEG

    Magnetoencephalogram studies done in AD patients show decreases in endogenous gamma synchronization. We will measure induced gamma entrainment using the GENUS device with EEG.

    Time frame: Baseline to 12 months

  5. Change from baseline in sleep

    The investigators will evaluate sleep quality using the Pittsburgh Sleep Quality Index

    Time frame: Baseline to 12 months

  6. Change from baseline in activity levels

    The investigators will evaluate activity levels using actigraphy

    Time frame: Baseline to 12 months

  7. Incidence of adverse events

    Adverse Events as a result of GENUS stimulation will be reported.

    Time frame: Baseline to 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for May 2027, 35 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 35 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Mar 20, 2023
StartActual
Jun 21, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05776641
Collaborators
Massachusetts Institute of Technology
Responsible party
Diane Chan (Neurologist, Massachusetts General Hospital) — Principal investigator
First posted
Mar 20, 2023
Start date
Jun 21, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Angelina Singavarapu, BS
Contact
gamma.wave@mit.edu
617-258-7723
Ana Lipsanopoulos, MA
Contact
anat13@mit.edu
617-258-7723
Diane Chan, MD PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion